612 related articles for article (PubMed ID: 20375418)
1. Predicting the EuroQol Group's EQ-5D index from CDC's "Healthy Days" in a US sample.
Jia H; Zack MM; Moriarty DG; Fryback DG
Med Decis Making; 2011; 31(1):174-85. PubMed ID: 20375418
[TBL] [Abstract][Full Text] [Related]
2. Estimating EuroQol EQ-5D scores from Population Healthy Days data.
Jia H; Lubetkin EI
Med Decis Making; 2008; 28(4):491-9. PubMed ID: 18556640
[TBL] [Abstract][Full Text] [Related]
3. Comparison of FACT- and EQ-5D-based utility scores in cancer.
Pickard AS; Ray S; Ganguli A; Cella D
Value Health; 2012; 15(2):305-11. PubMed ID: 22433762
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life measured using the EQ-5D-5L: South Australian population norms.
McCaffrey N; Kaambwa B; Currow DC; Ratcliffe J
Health Qual Life Outcomes; 2016 Sep; 14(1):133. PubMed ID: 27644755
[TBL] [Abstract][Full Text] [Related]
5. Health Condition Impacts in a Nationally Representative Cross-Sectional Survey Vary Substantially by Preference-Based Health Index.
Hanmer J; Cherepanov D; Palta M; Kaplan RM; Feeny D; Fryback DG
Med Decis Making; 2016 Feb; 36(2):264-74. PubMed ID: 26314728
[TBL] [Abstract][Full Text] [Related]
6. Comparison of different valuation methods for population health status measured by the EQ-5D in three European countries.
Bernert S; Fernández A; Haro JM; König HH; Alonso J; Vilagut G; Sevilla-Dedieu C; de Graaf R; Matschinger H; Heider D; Angermeyer MC;
Value Health; 2009; 12(5):750-8. PubMed ID: 19490564
[TBL] [Abstract][Full Text] [Related]
7. Mapping the EQ-5D index from the SF-12: US general population preferences in a nationally representative sample.
Sullivan PW; Ghushchyan V
Med Decis Making; 2006; 26(4):401-9. PubMed ID: 16855128
[TBL] [Abstract][Full Text] [Related]
8. A comparison of utility measurement using EQ-5D and SF-6D preference-based generic instruments in patients with rheumatoid arthritis.
Salaffi F; Carotti M; Ciapetti A; Gasparini S; Grassi W
Clin Exp Rheumatol; 2011; 29(4):661-71. PubMed ID: 21813061
[TBL] [Abstract][Full Text] [Related]
9. Preference-Based EQ-5D index scores for chronic conditions in the United States.
Sullivan PW; Ghushchyan V
Med Decis Making; 2006; 26(4):410-20. PubMed ID: 16855129
[TBL] [Abstract][Full Text] [Related]
10. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages?
Rutten-van Mölken MP; Oostenbrink JB; Tashkin DP; Burkhart D; Monz BU
Chest; 2006 Oct; 130(4):1117-28. PubMed ID: 17035446
[TBL] [Abstract][Full Text] [Related]
11. Assessing outcomes for cost-utility analysis in mental health interventions: mapping mental health specific outcome measure GHQ-12 onto EQ-5D-3L.
Lindkvist M; Feldman I
Health Qual Life Outcomes; 2016 Sep; 14(1):134. PubMed ID: 27644119
[TBL] [Abstract][Full Text] [Related]
12. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
[TBL] [Abstract][Full Text] [Related]
13. An investigation into the empirical validity of the EQ-5D and SF-6D based on hypothetical preferences in a general population.
Petrou S; Hockley C
Health Econ; 2005 Nov; 14(11):1169-89. PubMed ID: 15942981
[TBL] [Abstract][Full Text] [Related]
14. Mapping the SRS-22r questionnaire onto the EQ-5D-5L utility score in patients with adolescent idiopathic scoliosis.
Wong CKH; Cheung PWH; Samartzis D; Luk KD; Cheung KMC; Lam CLK; Cheung JPY
PLoS One; 2017; 12(4):e0175847. PubMed ID: 28414745
[TBL] [Abstract][Full Text] [Related]
15. Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease.
Moore A; Young CA; Hughes DA
Value Health; 2018 Nov; 21(11):1322-1329. PubMed ID: 30442280
[TBL] [Abstract][Full Text] [Related]
16. Mapping PROMIS Global Health Items to EuroQol (EQ-5D) Utility Scores Using Linear and Equipercentile Equating.
Thompson NR; Lapin BR; Katzan IL
Pharmacoeconomics; 2017 Nov; 35(11):1167-1176. PubMed ID: 28710740
[TBL] [Abstract][Full Text] [Related]
17. Mapping the English and Chinese versions of the Functional Assessment of Cancer Therapy-General to the EQ-5D utility index.
Cheung YB; Thumboo J; Gao F; Ng GY; Pang G; Koo WH; Sethi VK; Wee J; Goh C
Value Health; 2009; 12(2):371-6. PubMed ID: 18783392
[TBL] [Abstract][Full Text] [Related]
18. EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis.
Pickard AS; Gooderham M; Hartz S; Nicolay C
J Med Econ; 2017 Jan; 20(1):19-27. PubMed ID: 27471948
[TBL] [Abstract][Full Text] [Related]
19. Choice Defines QALYs: A US Valuation of the EQ-5D-5L.
Craig BM; Rand K
Med Care; 2018 Jun; 56(6):529-536. PubMed ID: 29668646
[TBL] [Abstract][Full Text] [Related]
20. Predicting EuroQoL EQ-5D preference scores from the SF-12 Health Survey in a nationally representative sample.
Lawrence WF; Fleishman JA
Med Decis Making; 2004; 24(2):160-9. PubMed ID: 15090102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
